Key points are not available for this paper at this time.
STUDY OBJECTIVES: To discern the frequency of torsades de pointes and QT prolongation in patients receiving intravenous erythromycin lactobionate; to examine the degree of QT prolongation and QT dispersion due to intravenous erythromycin in a typical clinical setting; and to identify any concurrent factors that might predispose patients to excessive QT prolongation or torsades de pointes while receiving intravenous erythromycin. DESIGN: Retrospective cohort trial. SETTING: A university teaching hospital. PATIENTS: All inpatients who received intravenous erythromycin lactobionate during a 1-year period. MEASUREMENTS AND MAIN RESULTS: The records of 278 consecutive patients were analyzed, of whom 49 had 12-lead electrocardiograms while receiving and not receiving erythromycin. The dosages of erythromycin ranged from 18-83 (42 +/- 18) mg/kg/day. Of the 49 patients, the baseline QTc was 432 +/- 39 msec, compared with 483 +/- 62 msec during erythromycin therapy (p or = 500 msec). Of the 278 patients prescribed intravenous erythromycin over the year, it caused torsades de pointes in just one (< or = 0.4%). CONCLUSION: Erythromycin lactobionate-induced torsades de pointes is rare, although QT prolongation is common. Some patients may be at risk for suffering torsades de pointes due to this agent, particularly if heart disease or other factors that may further delay ventricular repolarization are present.
Oberg et al. (Sun,) studied this question.